You Are Encouraged To Report Negative Side Effects Of Prescription Drugs To The Fda.

Tell your doctor if you have been vaccinated within 1 month before you start taking Gilenya. Ideas On Quick Strategies In Glaucoma | Guidance For That EyesYou should not get certain vaccines, called live attenuated vaccines, while taking Gilenya and for at least 2 months after stopping Gilenya treatment. The most common side effects with Gilenya were headache, abnormal liver tests, diarrhea, cough, flu, sinusitis, back pain, abdominal pain, and pain in arms or legs. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Disclaimer The foregoing release contains forward-looking statements that can be identified by words such as “potentially,” “commitment,” “committed,” “may,” “innovative,” or similar terms, or by express or implied discussions regarding potential new indications or labeling for Gilenya, potential marketing approvals for any investigational therapies for MS being developed at Novartis, or regarding potential future revenues from Gilenya and such investigational therapies for MS. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Gilenya will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that any investigational therapies for MS being developed at Novartis will be submitted or approved for sale in any market, or at any particular time.http://charlesriveratravel.bandonseaview.com/2016/08/29/a-guide-to-simple-methods-for-keratoconus/

For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/novartis-data-finds-relapsing-ms-patients-on-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-300329381.html

Leave a Reply

Your email address will not be published. Required fields are marked *